Cargando...
5PSQ-063 Response to abiraterone and enzalutamide in castrate-resistant prostate cancer in clinical practice
BACKGROUND: Abiraterone and enzalutamide are recommended for patients with metastatic castrate-resistant prostate cancer (mCRPC) who are chemotherapy-naive or have received treatment with docetaxel. Clinical practice guidelines do not explain the optimal sequence or combination of these agents. Sequ...
Guardado en:
| Publicado en: | Eur J Hosp Pharm |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMJ Group
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535567/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.417 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|